| Literature DB >> 24376797 |
Eroboghene H Otete1, Anand S Ahankari1, Helen Jones1, Kirsty J Bolton2, Caroline W Jordan3, Tim C Boswell4, Mark H Wilcox5, Neil M Ferguson6, Charles R Beck1, Richard L Puleston1.
Abstract
INTRODUCTION: Mathematical modelling of Clostridium difficile infection dynamics could contribute to the optimisation of strategies for its prevention and control. The objective of this systematic review was to summarise the available literature specifically identifying the quantitative parameters required for a compartmental mathematical model of Clostridium difficile transmission.Entities:
Mesh:
Year: 2013 PMID: 24376797 PMCID: PMC3869946 DOI: 10.1371/journal.pone.0084224
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1PRISMA flow diagram of the literature review process.
Summary of study characteristics for included studies (N=54).
|
|
|
|
|---|---|---|
|
| ||
| Cross-sectional studies | 32 | 59 |
| Case-control studies | 6 | 11 |
| Prospective cohort studies | 14 | 26 |
| Design unclear | 2 | 4 |
|
| ||
| Very high | 47 | 87 |
| High | 1 | 2 |
| Medium/low | 0 | 0 |
| Data unclear | 6 | 11 |
|
| ||
| Hospital inpatients (general/unspecified) | 34 | 63 |
| Hospital outpatients (general/unspecified) | 20 | 37 |
| Nursing/long-term care facility | 5 | 9 |
| All community cases within a circumscribed area | 3 | 6 |
| Renal patients | 2 | 4 |
| Organ/stem cell transplant patients | 6 | 11 |
| Other – HIV, neurology and psychiatric gerontology, surgery / gastroenterology, appendectomy, burns, gynaecological oncology, IBD | 8 | 15 |
|
| ||
| Toxin detection / immune assay | 51 | 94 |
| Stool culture | 18 | 33 |
| Polymerase chain reaction (PCR) ribotyping | 6 | 11 |
| Antigen detection | 1 | 2 |
| Multilocus sequence typing | 1 | 2 |
| Laboratory-diagnosed, methods unclear | 2 | 2 |
* Numbers do not sum to 54 as some studies include more than one population group
@ Numbers do not sum to 54 as some studies include more than one method of diagnosis
Studies providing limits on basic reproduction number.
|
|
|
|
|
|
|---|---|---|---|---|
| Lanzas [ | 2011 | A mathematical model for | January to December 2008 | Estimated basic reproduction numbers for variation in other parameters: Mean= 1.07, Median= 1.04. Range 0.55-1.99. New colonisations produced by asymptomatic or symptomatic patients’ averaged 0.4 new patients colonised without a protective response and 0.6 new patients colonised with a protective response |
| Noren [ | 2004 | 330 isolates from patients with toxin-positive diarrhoea were analysed by PCR ribotyping Secondary cases were linked to index cases using PCR ribotyping | February 1999 to January 2000 | For ribotype SE17 (UK ribotype 012), 7 index cases gave rise to 19 secondary cases. Mean: 2.6 secondary cases per index case (range 1-7). For ribotypes other than SE17: Mean 1.2 secondary cases per index case (range 1-4) |
Studies reporting data on incubation period.
|
|
|
|
|
|
|---|---|---|---|---|
| Samore [ | 1996 | 52 ‘index’ cases with diarrhoea and positive stool toxin assay were included; stool samples from hospital roommates, occupants of adjacent wards and the patient subsequently occupying the room were analysed for evidence of transmission | June to December 1992 | Interval between onset of exposure and onset of symptoms in 12 symptomatic contacts: 3-28 days, median 19 days. Interval between onset of exposure and positive culture in 19 asymptomatic contacts: 1-20 days, median 5 days |
| Walker [ | 2012 | Data of 218 enzyme immune assay positive patients from a hospital laboratory database were used to analyse potential ward-based contacts between patients | September 2007 to March 2010 | Incubation periods calculated: 61% of patients <=4wks. 13% of patients >12wks. Medians 18-33 days depending on possible links. IQRs 8-74 days, depending on possible links |
Studies reporting data on contact patterns.
|
|
|
|
|
|
|---|---|---|---|---|
| Hamel [ | 2010 | Multiple databases of 37697 patients used to identify 202 cases of CDI (identified by enzyme immunoassay for toxin A or B) and room-mate exposures. | April 2001 to March 2006. | Total roommate exposure was associated with CDI - Hazard Ratio (HR) total roommates/day 1.06 (1.00-1.12). After adjusting for confounders, HR=1.11 (1.03-1.19). |
| Pepin [ | 2012 | 2222 patients diagnosed with CDI were identified from a hospital database. Cases related to one another were found and verified using telephone number. | January 1998 to December 2009. | 5/1061 spouses and 3/501 children developed CDI. Attack rates were 4.71/1000 and 5.99/1000 respectively. |
| Samore [ | 1996 | 52 ‘index’ cases with diarrhoea and positive stool toxin assay were included; stool samples from hospital roommates, occupants of adjacent wards and the patient subsequently occupying the room were analysed for evidence of transmission. | June to December 1992. | 99 contacts were analysed; 12 had |
Studies reporting time interval between infection and onward transmission.
|
|
|
|
|
|
|---|---|---|---|---|
| Pepin [ | 2012 | 2222 patients diagnosed with CDI were identified from a hospital database. Cases related to one another were found and verified using telephone number. | January 1998 to December 2009. | 9 household contacts with CDI: 8/9 secondary cases developed within 2 months of the index case. |
| Walker [ | 2012 | Data of 218 EIA positive patients from a hospital laboratory database were used to analyse potential ward-based contacts between patients. | September 2007 to March 2010. | Minimum infectious period: 65% of transmissions ≤ 1wk, 82% ≤ 4wks, 10% > 8wks. Medians 1-8 days depending on possible links. IQRs 0-33 days, depending on possible links. |
Studies reporting data on recovery rate.
|
|
|
|
|
|
|---|---|---|---|---|
| Alanazi [ | 2012 | Pediatric patients undergoing hemopoietic stem cell transplantation | 2001-2009 | Responded to therapy with metronidazole: 78/80 (98%). |
| Bilgrami [ | 1999 | Blood stem cell transplant patients | Mar 1993- Aug 1996 | Recovered after initial therapy with metronidazole and/or vancomycin: 14/14 (100%) - 1 patient had a relapse but recovered afterwards. |
| Bouza [ | 1995 | Hospital inpatients | 1994 (one year) | Recovered after initial therapy (oral vancomycin or metronidazole): 76/83 (92%) |
| Khan [ | 2012 | Hospital inpatients (≥15 years) | 2006-2009 | Cure rate (resolution of diarrhoea by day 6 of treatment, and negative assays on days 6 and 10): 96/123 (78%). |
| Kim [ | 2011 | Hospital inpatients | Sep 2008-Jan 2010 | Diarrhoea stopped without treatment: 49/189 (26%). Clinical cure rate (with treatment): 118/140 (84%). ‘Global cure’ i.e. cured without recurrence: 93/140 (66%). |
| Kim [ | 2012 | Adult hospital inpatients (>18 years) | 2004-2008 | 2008 cohort - ‘Improved' without therapy other than discontinuing antibiotics: 235/1367 (17%) – (NB the 1367 quoted includes patients who went on to have treatment). ‘Improved' with oral metronidazole: 796/846 (94%). |
| Kyne [ | 1998 | Hospital inpatients | Jan-Jun 1995 | Resolution of symptoms: 38/73 (52%). Of the 73 patients, 62 had had metronidazole or vancomycin therapy, 11 had no treatment. |
| Vesteinsdottir [ | 2012 | All patients in Iceland (hospital-acquired and community-acquired CDI) | July 2010-June 2011 | Recovery rate from primary CDI with 1 course of antibiotics: 70/93 (75%) – 69 patients had metronidazole, 1 had vancomycin. |